Obesity's cardiometabolic cascade operates through four converging pathways: upper-airway collapsibility driving OSAS, ectopic fat and insulin resistance triggering MASLD, chronic inflammation generating small dense LDL and suppressing HDL-C, and renin-angiotensin-aldosterone system activation causing glomerular hyperfiltration that accelerates CKD — a constellation the authors term obesity-related glomerulopathy (ORG). GLP-1 receptor agonists and SGLT-2 inhibitors demonstrate efficacy across all four domains simultaneously, while Very Low Energy Ketogenic Therapy (VLEKT) surfaces as a structured dietary intervention improving hepatic steatosis and cardiovascular risk markers.
This is fundamentally a narrative synthesis rather than original data generation, which tempers its evidential weight — yet its clinical utility lies precisely in mapping mechanistic crosstalk that fragmented organ-specific literature obscures. The convergence of GLP-1RAs and SGLT-2 inhibitors as multi-target agents represents the most consequential shift in obesity medicine this decade, moving treatment philosophy from weight-centric to complication-centric. VLEKT's inclusion is notable: ketogenic protocols have historically faced skepticism in nephrology due to protein-load concerns, so positioning VLEKT as CKD-adjacent warrants scrutiny in future prospective trials. For clinicians and health-conscious adults, the central actionable message is that managing visceral adiposity earlier — before the OSAS-MASLD-dyslipidemia-CKD quartet fully establishes — offers exponentially greater returns than late-stage pharmacological rescue. Incremental framing, but the mechanistic synthesis adds genuine clinical orientation.
